TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics, a biopharmaceutical company specializing in T-cell receptor engineered therapies for cancer, will participate in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics, a biopharmaceutical company specializing in T-cell receptor engineered therapies for cancer, will participate in two upcoming investor conferences. These include the Jefferies London Healthcare Conference on November 18, 2021, and the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. Webcasts of each fireside chat will be accessible for on-demand listening on the company’s website. TScan's lead therapies, TSC-100 and TSC-101, target hematologic malignancies and aim to prevent leukemia relapse.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was +1.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate virtually at the following upcoming investor conferences:
- Jefferies London Healthcare Conference; the fireside chat will be available for on-demand listening beginning Thursday, November 18, 2021, at 3:00 a.m. ET
- Evercore ISI 4th Annual HealthCONx Conference; the fireside chat will be held on Thursday, December 2, 2021, at 11:20 a.m. ET
Webcasts of each fireside chat will be available and will remain archived on the “Events and Presentations” section of the Company’s website at ir.tscan.com.
About TScan Therapeutics, Inc.
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Contacts
TScan Therapeutics, Inc.
Heather Savelle
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Media Contact:
David Rosen
Argot Partners
212-600-1902
david.rosen@argotpartners.com
Investor Contact:
Sherri Spear
Argot Partners
212-600-1902
sherri@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.